SA
IDXX icon

Strategic Advocates’s Idexx Laboratories IDXX Stock Holding History

Strategic Advocates’s Portfolio IDXX Stock Details IDXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$54.8K Buy
104
+35
+51% +$19.6K 0.21% 80
2026
Q1 		$38.8K Buy
69
+61
+763% +$39.1K 0.17% 91
2025
Q4 		$5.46K Hold
8
– – ﹤0.01% 421
2025
Q3 		$5.11K Buy
+8
New +$4.86K ﹤0.01% 406

Other funds holding IDXX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Strategic Advocates's IDXX Position: Q2 2026 in Review

Strategic Advocates increased its Idexx Laboratories (IDXX) stake by 51% in Q2 2026, buying an estimated $19.6K and bringing the position to 104 shares worth $54.8K. The position accounts for 0.21% of the portfolio, ranked #80.

Strategic Advocates first reported a position in IDXX in Q3 2025 and has held it in 4 quarters since. 1,302 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.

  • Strategic Advocates held 104 shares of Idexx Laboratories worth $54.8K as of Q2 2026.
  • Strategic Advocates bought 35 Idexx Laboratories shares in Q2 2026, an estimated $19.6K.
  • Idexx Laboratories made up 0.21% of Strategic Advocates's portfolio in Q2 2026, its #80 holding.
  • Strategic Advocates first reported a position in Idexx Laboratories in Q3 2025 and has held it in 4 quarters since.
  • 1,302 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.

Based on Strategic Advocates's 13F filing for Q2 2026, filed 13 Aug 2026.